Neurological conditions need longitudinal data most
Your patients' conditions evolve over months and years — migraine attack frequency, seizure control, MS relapses, cognitive decline trajectories. That data exists across EHRs, imaging centers, rehab facilities, and patient diaries. Sguardo brings it into one longitudinal view so you can see progression, not just the latest visit.
Migraine diaries synced from the patient app. AED and DMT adherence from pharmacy claims. Cognitive screening scores tracked over time. HCC coding for the full neurological condition set. All in one normalized record.
Request Limited Private Beta Invite All Specialties
Built for how neurologists practice
Neurological care is longitudinal, complex, and data-intensive. Sguardo surfaces the patterns that matter across visits, providers, and systems — for migraine, dementia, epilepsy, MS, and stroke.
Migraine diary and trigger identification
Patients log attacks in the Sguardo app between visits: date, duration, severity, aura, triggers, and acute medication taken. That diary syncs into your provider view in real time. You see attack frequency trends across months, not just what the patient recalls in the exam room. Trigger patterns — sleep, stress, hormonal cycles, food, weather — are surfaced automatically from the logged data so you can counsel specifically, not generically.
Migraine PROs: HIT-6 and MIDAS
Attack frequency alone understates migraine burden. HIT-6 and MIDAS capture the functional impact: missed workdays, reduced-activity days, and disability from headache. Sguardo tracks both scores over time so you can demonstrate treatment response objectively — to the patient, to payers, and to CGRP authorization requests. When scores improve alongside reduced attack frequency, the case for therapy continuation is built into the record.
Acute and preventive medication tracking
Track triptans, CGRP antagonists, preventives (topiramate, amitriptyline, valproate, beta-blockers), and OTC analgesics from pharmacy claims. PDC calculations flag patients with low preventive adherence before you see them. Acute medication overuse — a driver of chronification — is flagged when fill patterns suggest more than 10 use-days per month.
Cognitive screening and dementia progression
Track MMSE and MoCA scores at each visit to build a longitudinal cognitive trajectory. When a patient's score drops 2+ points, Sguardo flags it in context — showing the previous scores and the rate of change, not just the latest number. Behavioral and psychological symptoms of dementia (BPSD) logged by caregivers in structured notes are available alongside clinical data at each visit.
AED & DMT medication adherence
Antiepileptic drug adherence directly predicts seizure control. Disease-modifying therapy adherence determines MS progression. Sguardo computes PDC from pharmacy claims and flags patients below the 80% threshold before they break through. Drug levels (levetiracetam, valproic acid, carbamazepine) are trended alongside adherence data.
Stroke risk factor monitoring
Atrial fibrillation, hypertension, diabetes, hyperlipidemia — your stroke patients have comorbidities managed by other providers. Sguardo aggregates BP trends, HbA1c, anticoagulation PDC, and lipid panels into one view so secondary prevention gaps don't fall through the cracks between specialties.
Dementia care across the full care team
Dementia management involves the neurologist, PCP, and family caregivers — often with fragmented communication and no shared record. Sguardo brings the longitudinal cognitive picture into one place and supports caregivers between visits.
Caregiver-reported behavioral tracking
Family caregivers use the Sguardo patient app to log behavioral and psychological symptoms between visits: agitation, sleep disturbance, hallucinations, wandering, and functional changes in ADLs. When the patient comes in, you see a structured symptom log covering the weeks since the last visit — not a caregiver's recalled summary under time pressure.
Dementia medication management
Cholinesterase inhibitor and memantine adherence from pharmacy claims. Anticholinergic burden scoring across the full medication list — flagging agents from other prescribers that work against cognitive function. Polypharmacy risk is high in this population; Sguardo surfaces the complete cross-provider medication picture at the point of care.
Neurologist, PCP, and family coordination
Dementia care requires shared situational awareness across providers who rarely communicate in real time. Sguardo surfaces the same longitudinal record — cognitive scores, behavioral logs, medication changes, and care plan updates — to each authorized member of the care team. The neurologist sees what the PCP changed. The PCP sees what the neurologist found. The family has access to what they need to support care at home.
Quality measures and HCC coding for neurology
Neurological HCC coding
Epilepsy (HCC 79), stroke/TIA (HCC 100–103), Parkinson’s (HCC 78), MS (HCC 77), ALS (HCC 75), dementia (HCC 51–52) — neurological conditions carry significant HCC weight. Sguardo flags conditions from prior years that need recapture at annual visits, with estimated RAF impact per patient.
Stroke & TIA secondary prevention
Anticoagulation for A-fib, statin therapy, BP control, antiplatelet therapy. Sguardo computes compliance rates for each secondary prevention intervention and identifies patients with incomplete coverage before their next scheduled visit.
Epilepsy quality measures
Seizure freedom rates, AED adherence, therapeutic drug level monitoring, counseling documentation (driving, pregnancy, SUDEP). Post-discharge follow-up tracking for seizure-related admissions. Track outcomes across your epilepsy panel in one view.
Migraine quality and CGRP documentation
Adequate trial of preventive therapy is a prior authorization requirement for CGRP inhibitors. Sguardo tracks the structured trial history — agent, dose, duration, response, and reason for discontinuation — so the documentation is built during care, not assembled retroactively when a PA is denied.
Dementia care quality
Cognitive assessment documentation (MMSE, MoCA at each visit), caregiver burden screening, advance care planning documentation, and annual medication review for anticholinergic burden. Dementia HCC codes (51–52) are high-value for risk adjustment and require accurate annual recapture.
Lab & imaging interval tracking
Drug levels (levetiracetam, valproic acid, carbamazepine), renal function for contrast studies, MRI interval tracking for MS and tumor surveillance. Reference ranges are context-aware — therapeutic drug levels have different targets than standard lab values, and Sguardo applies the right range automatically.
